Research | Open | Published:
Lithospermic acid attenuates 1-methyl-4-phenylpyridine-induced neurotoxicity by blocking neuronal apoptotic and neuroinflammatory pathways
Journal of Biomedical Sciencevolume 22, Article number: 37 (2015)
Parkinson’s disease is the second most common neurodegenerative disorders after Alzheimer’s disease. The main cause of the disease is the massive degeneration of dopaminergic neurons in the substantia nigra. Neuronal apoptosis and neuroinflammation are thought to be the key contributors to the neuronal degeneration.
Both CATH.a cells and ICR mice were treated with 1-methyl-4-phenylpyridin (MPP+) to induce neurotoxicity in vitro and in vivo. Western blotting and immunohistochemistry were also used to analyse neurotoxicity, neuroinflammation and aberrant neurogenesis in vivo. The experiment in CATH.a cells showed that the treatment of MPP+ impaired intake of cell membrane and activated caspase system, suggesting that the neurotoxic mechanisms of MPP+ might include both necrosis and apoptosis. Pretreatment of lithospermic acid might prevent these toxicities. Lithospermic acid possesses specific inhibitory effect on caspase 3. In mitochondria, MPP+ caused mitochondrial depolarization and induced endoplasmic reticulum stress via increasing expression of chaperone protein, GRP-78. All the effects mentioned above were reduced by lithospermic acid. In animal model, the immunohistochemistry of mice brain sections revealed that MPP+ decreased the amount of dopaminergic neurons, enhanced microglia activation, promoted astrogliosis in both substantia nigra and hippocampus, and MPP+ provoked the aberrant neurogenesis in hippocampus. Lithospermic acid significantly attenuates all of these effects induced by MPP+.
Lithospermic acid is a potential candidate drug for the novel therapeutic intervention on Parkinson’s disease.
Parkinson’s disease (PD) is characterized by the selective loss of dopaminergic neurons and neuroinflammation in the substantia nigra (SN) [1–3]. Even after numerous studies, the cause of dopaminergic cell degeneration in SN of PD patients still has not been identified with certainty. Therefore, several experimental models for the therapeutic research on PD have been developed to investigate the pathogenesis and pathophysiology of PD [4, 5].
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that can induce symptoms similar to those observed in PD patients  and induces selective loss of dopaminergic neurons in SN of mice [4, 5]. MPTP must be converted into 1-methyl-4- phenylpyridine (MPP+) in the glial cells and then taken up by dopaminergic neurons via the dopamine transporter. Consequently, MPP+ is concentrated inside the mitochondria where it potently inhibits complex I of the electron transport system . This result in ATP depletion, loss of mitochondrial membrane potential, and the formation of reactive oxygen species (ROS) and reactive nitrogen species (RNS), activation of caspase-9 and −3 , increasing intracellular Ca2+ concentrations , enhancing endoplasmic reticulum (ER) stress [10, 11], and results in programmed cell death.
Several lines of evidence suggest that apoptotic cell death of dopaminergic neurons in PD is driven in part by neuroinflammation [12, 13]. The production of toxic levels of ROS and RNS by activated microglia is believed to be a major threat for dopaminergic neurons survival . Persistent microglial activation has been detected in the SN of humans and mice [14, 15]. Moreover, the short-term MPTP induced a significant increase in the numbers of newborn type1 and type2a neurons which represent a subpopulation of rarely dividing cells with glial characteristics, which are suggested to give rise to immature neurons in the course of adult neurogenesis .
A variety of polyphenolic compounds has been isolated from Tournefortia sarmentosa Lam. (Boraginaceae) (Chinese name: Teng Zi Dan), widely used in Taiwan as a detoxicant and anti-inflammatory agent . Most of these polyphenolic compounds possess antioxidative activity, including tournefolic acid B (TAB), TAB methyl ester (TABM), and lithospermic acid (LSA). The TAB and TABM exhibit neuroprotective potency against glutamate-, NMDA-, and Aβ-mediated neurotoxicity [18–20]. LSA was also extracted from Salvia miltiorrhiza Bge (Labiatae)  and Origanum vulgare , and has been investigated to possesses the effects on anti-oxidation and anti-inflammation ; and anti-atherosclerosis .
In this study, we use both cell and animal models for PD. To study the MPP+-mediated neurotoxicity in vitro, murine dopaminergic neuron cell line (CATH.a) was employed according on their activity to synthesize abundant dopamine and norepinephrine and expressing the appropriate catecholaminergic biosynthetic enzymes, tyrosine hydroxylase (TH) and dopamine β-hydroxylase . For comparison, primary cortical neurons, in which doparminergic neuron is not the major neuronal type, were also employed. On the other hand, to examine the MPP+-mediated neurotoxicity, neuroinflammation, and neurogenesis in vivo, intracerebral ventricle (icv)-injection of MPP+ in mice was used. The objective of this study was to investigate influence of LSA on MPP+-induced neurotoxicity alone and neurotoxicity with neuroinflammation and neurogenesis in cell and animal models, respectively. Our results demonstrated that LSA effectively reduced MPP+-induced neurotoxicity in vitro and in vivo. Furthermore, LSA effectively attenuated neuroinflammationm and the aberrant neurogenesis in vivo.
Cell cultures and treatments
CATH.a cells were cultured in RPMI 1640 medium containing 10 units/ml penicillin, 10 μg/ml streptomycin, 4 % fatal bovine serum and 6 % horse serum.
Primary cultures of neonatal cortical neurons were prepared from the cerebral cortex of Sprague Dawley rat pups at postnatal day 1 as described previously . Briefly, pups were anesthetized with ether and sacrificed by decapitation. The cortex was digested in 0.5 mg/ml papain at 37 °C for 15 min and dissociated in Hibernate A medium (containing B27 supplement) by trituration. Cells were plated (5 × 104 cells/cm2) onto poly-L-lysine-coated plates and maintained in Neurobasal medium containing B27 supplement, 10 units/ml penicillin, 10 μg/ml streptomycin, and 0.5 μg/ml glutamine (5 % CO2/9 % O2) for 3 days. Cells were then exposed to cytosine-β-D arabinofuranoside (5 μM) for 1 day to eliminate the proliferation of non-neuronal cells. The cells were used for the experiment on the fifth day.
CATH.a cells or cortical neurons were pre-treated with vehicle, LSA or TAB for 30 min and then MPP+ were added into the culture for inducing neurotoxicity.
Measurement of cell viability
The calcein/ethidium homodimer-1 staining and the reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) were used to evaluate cell viability. Cells were loaded with 1 μM of both calcein AM and ethidium homodimer-1 at room temperature for 30 min. The cells were observed by laser-scanning confocal fluorescence microscope (Leica CS SP, Wetzlar, Germany; Zeiss LSM780, Carl Zeiss, Jena, Germany). Cells were incubated with 0.5 mg/ml MTT for 1 h. The formazan particles were dissolved with dimethyl sulfoxide (DMSO). OD600 nm was measured using an ELISA reader.
Measurement of superoxide anion (O2 −.)
The intracellular level of O2 −. was measured by dihydroethidium assay as described previously . Treated cells were loaded with 3.2 μM dihydroethidium at 37 °C for 30 min and then observed by a Leica DMIRB fluorescence microscope. The intensity of fluorescence in nuclear position was measured by using MetaMorph software (Universal Imaging Co., West Chester, PA).
Determination of mitochondrial membrane potential
Cells were treated with MPP+ (300 μM) or MPP+ combined with LSA (100 μM) for 2 hours, and then cells were loaded with 100 nM Tetramethyl Rhodamine Methyl Ester (TMRM) at 37 °C for 20 min. After wash with Hanks’ balanced salt solution (HBSS; 137 mM NaCl, 5.4 mM KCl, 0.4 mM KH2PO4, 4.2 mM NaHCO3, 0.5 mM MgCl2, 0.6 mM MgSO4, and 5.6 mM D-glucose, pH 7.4), cells were incubated in HBSS containing 2 mM CaCl2. The fluorescence of TMRM was detected by a Leica DMIRB fluorescence microscope with an excitation wavelength of 555 nm.
For Western blot analysis, samples (6 μg protein) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (15 % gels) and were then transferred to PVDF membranes. The primary antibodies used were as follows: mouse monoclonal antibody to actin and α-spectrin (Invitrogen), rabbit polyclonal antibody to caspase 3 (Millipore), cleaved caspase 3, caspase 7, cleaved caspase 7, caspase 9, cleaved caspase 9, caspase 12, cleaved poly ADP ribose polymerase (PARP), c-jun N-terminal kinase (JNK), pJNK(T183/Y185) (Cell signalling) and 78 kDa glucose-regulated protein (GRP-78) (Santa Cruz). The secondary antibodies were anti-rabbit IgG antibody conjugated with horseradish peroxidase (GE Healthcare) and anti-mouse IgG antibody conjugated with horseradish peroxidase (Jackson ImmunoResearch). Enhanced chemiluminescence detection reagents (GE Healthcare) were used for detection. Bands were quantified using Fujifilm LAS-3000 Luminescent Image Analyzer (Tokyo, Japan).
Animals and treatment
The Institutional Animal Care and Use Committee at the National Research Institution of Chinese Medicine approved the animal protocol (IACUC No: 95-A-08). Six week-old male ICR mice were housed for 1 week under standard conditions at 25 ± 2 °C with a 12-h light/dark cycle and were allowed free access to water and standard chow. Administration (icv) of MPP+ (12 μg in 2 μl saline) was performed unilaterally on male ICR mice (8 weeks old). The mice were anesthetized with intraperitoneal (ip) chloral hydrate (Sigma; 0.4 g/kg body weight, maintained with 0.1 g/kg hourly) and fixed into a stereotaxic apparatus. The dorsal surface of the skull was exposed with a midline incision, and a burr hole was drilled at the following coordinates: anteroposterior, 0.22 mm caudal to bregma and 1 mm right lateral to midline. A 10-μl Hamilton syringe fitted with a 25-gauge needle was pre-loaded by 1 μl MPP+ solution (12 μg MPP+ in 1 μl saline) followed by 1 μl LSA solution (5 μg LSA in 1 μl saline). The injection syringe was placed over the burr hole and lowered 2.5 mm into the surface of the brain, and the solution was injected at a rate of 0.2 μl/min. The needle was then left in place for 2 min before it was slowly retracted. Control animals were injected with saline. MPP+ is injected into lateral ventricle to induce a Parkinson-like syndrome and lost of dopaminergic neurons in SNPc, and the proper dose is determined by trial test. The final amount of MPP injected was set at 12 μg MPP+.
At day 5 post MPP+ injection and vehicle injection, mice were deeply anesthetized with chloral hydrate and perfused through the heart with 30 ml of saline followed by 30 ml of fixative solution containing 4 % formaldehyde in saline. The brain was removed, post-fixed in 4 % formaldehyde for 18 h at 4 °C and cryoprotected in 30 % sucrose solution in 0.1 M phosphate-buffered saline (PBS). A cryostat was used to cut 30-μm coronal sections through the dorsal hippocampus, which were collected serially in PBS.
Brain sections were incubated in blocking solution (PBS containing 5 % normal goat serum, 2 % Triton X-100, 0.02 % bovine serum albumin) overnight at 4 °C and left overnight at 4 °C in staining solution (PBS containing 5 % normal goat serum, 0.25 % Triton X-100, 0.02 % bovine serum albumin) with primary antibodies, including mouse monoclonal antibody to glial fibrillary acid protein (GFAP) and tyrosin hydrolase (TH) (Invitrogen); rabbit polyclonal antibody to doublecortin (Abcam); and mouse monoclonal antibody to ionized calcium-binding adaptor molecule-1 (Iba-1, Abcam). Sections were then incubated in staining solution containing Hoechst33258 (Invitrogen, 2 μg/ml), Fluorescein isothiocyanate-conjugated goat anti-mouse IgG and cy5-conjugated goat anti-rabbit IgG or cy5-conjugated goat anti-rabbit IgG (1:200; Jackson ImmunoResearch) in the dark overnight at 4 °C. Sections were then washed in PBS and mounted with Aqua Poly/Mount (Polyscience Inc., Warrington, PA, USA). The sliced tissues were examined using a laser-scanning confocal microscope (Zeiss LSM780; Carl Zeiss, Jena, Germany).
Quantitative immunofluorescence analysis
All analyses were calculated within a field (250 × 250 μm2) of substantia nigra pars reticulata (SNpr), substantia nigra pars compacta (SNpc), Cornu Ammonis (CA)1 and dentate gyrus (DG). The expression of GFAP and Iba-1 expression was calculated from the immunoreactivity (IR) of each protein that displayed as the optical density (arbitrary unit) of each image.
The results are expressed as the mean ± standard deviation (S.D.) and were analyzed by analysis of variance (ANOVA) with post hoc multiple comparisons corrected with Bonferroni tests.
MPP+ mediates neurotoxicity in CATH.a cells and cortical neurons through distinct mechanisms
Treatment with MPP+ elicited cell death of CATH.a cells and cortical neurons in a concentration-dependent manner as determined by MTT reduction (Fig. 1a). MPP+ (300 μM) elicited cell death of CATH.a cells and cortical neurons by 51.65 ± 2.80 % and 52.66 ± 10.12 %, respectively. Morphologically, MPP+-provoked cell death of CATH.a cells and cortical neurons coincided with the appearance of cell atrophy and discontinuous neurites, respectively (Fig. 1b). Proteolytically, treatment with MPP+ induced cleavage of α-spectrin in cortical neurons but not in CATH.a cells. In cortical neurons, both the 150- and 145-kDa protein fragments (the activity of calpain), but not the 120-kDa fragment (the activity of caspase 3), were significantly appeared after the treatment of MPP+ (Fig. 1c, d).
LSA protect CATH.a cells but not cortical neurons against MPP+-mediated neurotoxicity
The effects of TABM and LSA on MPP+-induced neurotoxicity were investigated. From Fig. 1a, the concentration of MPP+ to induce 50 % cell death is 250 μM. Therefore, in this assay 250 mM MPP+ were adopted. The structure of TABM and LSA were showed in Fig. 2a. TABM and LSA at 100 μM did not significantly alter the cell viability of both cells (Data not shown). To cortical neurons, both TABM and LSA fail to ameliorate the detrimental effect of MPP+ (Fig. 2b, c). To CATH.a cells, the MPP+-mediated cell death was 33.06 % attenuated by 100 μM TABM (Fig. 2b), and was significantly attenuated by LSA in a concentration-dependent manner. LSA at 50 and 100 μM abrogated MPP+-mediated CATH.a cell death by 42.29 % and 83.19 %, respectively (Fig. 2c).
For determining the MPP+-mediated death pathways of CATH.a cells, calcein/ethidium homodimer-1 staining was employed. Treatment with MPP+ elicited both apoptosis and necrosis of CATH.a cells in a concentration-dependent manner (Fig. 3). MPP+ (400 μM) did not significantly affect calcein fluorescence (apoptosis), and elicited increase of ethidium homodimer-1 fluorescence (necrosis) by 9.35 folds of control. On the other hand, 600 μM MPP+ elicited reduction of calcein fluorescence and increase of ethidium homodimer-1 fluorescence by 39.25 % and 11.58 folds of control, respectively, and 50 μM LSA attenuated those values to 11.40 % and 6.17 folds of control (Fig. 3).
LSA blocked the MPP+-induced accumulation of superoxide anion and decrease of mitochondrial membrane potential
Dihydroethidium was used to measure the intracellular level of superoxide anion (O2 −.). Treatment with MPP+ significantly provoked O2 −. accumulation initially at 30 min and peaked at 120 min (Fig. 4). Treatment with MPP+ (300 μM ) for 30, 90, and 120 min elevated the level of O2 −. to 167.3 ± 50.9, 234.9 ± 53.9, and 242.9 ± 20.9 % of control, respectively. LSA (100 μM) diminished the MPP+-induced O2 −. accumulation by 55.37 % (Fig. 4b).
TMRM was used to verify whether LSA modulated the mitochondrial membrane potential. Treatment with MPP+ significantly diminished mitochondrial membrane potential as soon as at 30 min (Fig. 4). Treatment with 300 μM MPP+ for 30, 90, and 120 min decreased the level of membrane potential to 30.93 ± 1.23, 26.45 ± 1.29, and 21.03 ± 4.07 % of control, respectively. LSA (100 μM) significantly recovered the MPP+-induced decrease of membrane potential by 17.23 % (Fig. 4).
LSA Blocked the MPP+-Induced Pro-apoptotic responses
MPP+ time-dependently induced ER stress in CATH.a cells and increased expression of ER chaperones (GRP-78). MPP+ also triggered apoptosis by decreasing the level of the caspase 7 and 9, and increasing the level of cleaved caspase 3 and PARP. Treatment with MPP+ (300 μM ) for 24 hour significantly provoked GRP-78, caspase 7, caspase 9, cleaved caspase 3 and cleaved PARP to 252.48 ± 55.90, 48.60 ± 11.87, 49.73 ± 7.34, 170.39 ± 9.12 and 215.28 ± 41.17 of the control, respectively (Fig. 5a). LSA treatment significant prevented the level increase of GRP-78, cleaved caspase 3 and cleaved PARP. Treatment with MPP+ (300 μM ) for 8 hour significantly provoked GRP-78, caspase 7, caspase 9, cleaved caspase 3 and cleaved PARP to 162.63 ± 32.50, 73.71 ± 6.32, 63.14 ± 19.45, 166.39 ± 8.88 and 156.78 ± 25.04 of the control, respectively (Fig. 5b). LSA (100 μM) diminished the MPP+-induced level increase of GRP-78, cleaved caspase 3 and cleaved PARP to 86.38 ± 34.49, 124.76 ± 6.41 and 89.18 ± 16.99 of the control, respectively (Fig. 5b). Alternatively, LSA did not significantly affected MPP+-induced level decrease of caspase 7 and caspase 9. These results indicate that LSA may protect Cath.a cells against MPP+ activated ER stress and the associated apoptosis specifically target on caspase 3, but not on caspase 7 and 9.
Icv-MPP+-injection-induced lost of dopaminergic neurons in SNpc were attenuated by icv-LSA-injection
To explore the in vivo neurotoxicity of MPP+ and neuroprotective activity of LSA, the intracerebral ventricular injection of MPP+ (icv-MPP+-injection, 12 μg in 2 μl saline) alone or MPP+ combined with LSA (icv-MPP+-LSA-injection, 12 μg and 5 μg, respectively, in saline) were performed at single-side lateral ventricle of ICR mice. The mice were sacrificed 5 days later and the survival of the dopaminergic neurons were detected by immunostaining of TH. The results showed that icv-MPP+-injection reduced the TH-immunoreactivity in ipsilateral and contralateral side of SNpc to 51.2 ± 5.1 % and 70.86 ± 6.0 % of the control, respectively (Fig. 6). Co-treatment of LSA with MPP+ recovered the lost TH-immunoreactivity in ipsilateral side of SNpc to 64.7 ± 6.9 % and 83.89 ± 16.3 % of the control, respectively.
Icv-MPP+-injection-induced activation of microglia in SNpr and CA1 were attenuated by icv-LSA-injection
To examine the pro-inflammatory effects of MPP+, astrocytes and microglia were detected by immunostained with anti-GFAP and anti-Iba-1 antibodies, respectively. The results showed that icv-MPP+-injection increased the GFAP-postive astrocytes in CA1 area (to 138.9 % of the control) but not in SNpc and SNpr. The increased GFAP-positive astrocytes in CA1 area was attenuated by the co-treatment of LSA with MPP+ (to 101.5 % of the control). On the other hand, icv-MPP+-injection increased the Iba-1-postive microglia in both SNpr and CA1 area to 176 % and 9 folds of the control, respectively (Fig. 7). Co-treatment of LSA with MPP+ reduced the Iba-1-postive microglia in SNpr and CA1 area to 118 % and 4.3 folds of the control, respectively.
Icv-MPP+-injection-induced activation of radial glial-like stem cells and new-borne neurons in subgranular zone were attenuated by icv-LSA-injection
To examine the promoting effects of MPP+ on neurogenesis, the radial glial-like stem cells and the new-borne neurons were detected by immunostained with anti-GFAP and anti-doublecortin antibodies, respectively. The results showed that icv-MPP+-injection increased the GFAP-positive astrocytes/radial glial-like stem cells and doublecortin-positive new borne neurons in DG area to 291 % and 142 % of the control, respectively (Fig. 8). Co-treatment of LSA with MPP+ reduced these value to 128.7 % and 73.3 % folds of the control, respectively.
In the present study, the in vitro model (CATH.a cells, a dopaminergic neuron cell line) demonstrated that LSA abrogated MPP+-mediated neurotoxicity as determined by MTT reduction, calcein/ethidium homodimer-1 staining, and morphological observation. LSA attenuated the MPP+-mediated effects, including accumulation of O2 −., decrease of mitochondrial membrane potential, activation of the caspase cascade, and thereby protected CATH.a cells against MPP+-mediated neurotoxicity. Both necrosis and apoptosis are implicated in this neurotoxicity. Moreover, the in vivo model (icv-MPP+-injection of ICR mice) demonstrated that LSA effectively attenuate MPP+-mediated loss of dopaminergic neurons in SNpc, astrogliosis in hippocampus, microglial activation in both SNpr and CA1 areas, and aberrant neurogenesis in hippocampus.
In the in vitro assay, LSA and TAB were added into cell culture 30 min before the stimulation of MPP+ to prevent those pre-mixed with MPP+. In the in vivo assay, LSA solution was injected with MPP+ solution in the same syringe but without pre-mixed.
Previously, MPP+ has been suggested to induce neurotoxicity in dopaminergic neurons . For verifying the above statement, dose response of MPP+-mediated neurotoxicity was performed on two different cell types (i.e. CATH.a cells and cortical neurons). CATH.a cells, a mouse brain-derived catecholaminergic neuron cell, synthesizes abundant dopamine and norepinephrine and expresses the appropriate TH and dopamine β-hydroxylase . Previously, CATH.a cells administrated with 200–1000 μM MPP+ has been employed to be a cell model for the mechanism studies on Parkinson’s diseases . Besides the dopaminergic neurons, the primary cortical neurons have also been reported to be accessible to MPP+-mediated neurotoxicity [28, 29]. In our present study, we use both CATH.a cell line and primary cortical neurons to study the neurotoxic specificity mediated by MPP+. Our results indicated that MPP+ mediates distinct death pathway in CATH.a cells and the primary cortical neurons although the dose response between these two cell types was similar. The calpain-dependent cleavage of α-spectrin is involved in the death of primary cortical neurons, but not of CATH.a cells. The reason may be due to that CATH.a cells is not a neurite-bearing mature neurons [19, 30] and which may explain why LSA fail to protect the primary cortical neurons against MPP+-mediated neuron death. The previous reports suggested that calpain plays a central role in MPP+ mediates cell death in spinal cord motoneurons  and cerebellar granule neurons  may supported this speculation.
Mitochondrion is involved in the activation of caspase 9 mediating by cytochrome c release. Therefore, the mitochondrion is a pivotal organelle implicating in apoptosis . Recently, ER has attracted attention as an intracellular compartment in which disturbance of calcium homeostasis may contribute to pathological processes culminating in neuronal injury . Mitochondrial superoxide anion production and membrane potential loss has been reported to be the primitive mechanism of MPP+-mediated neuron death [35, 36]. In CATH.a cells, we also find that MPP+-induced superoxide anion production and mitochondrial membrane potential loss. These mitochondrial effects were attenuated by LSA treatment suggested that LSA may prevent the primitive mechanism of MPP+-mediated neuron death on mitochondria.
MPP+-induced toxicity seems to involve activation of unfolding protein response (UPR) and ubiquitin–proteasome system (UPS) dysfunction. In cell lines and primary dopaminergic neurons, MPP+ activates UPR; however, which branches are upregulated varies by cell type [10, 11]. Many studies have demonstrated the induction of at least some markers of apoptosis by MPP+ . Exactly how MPP+ leads to cell death in dopaminergic neurons is still unclear . Many studies have suggested that prolonged and severe UPR can lead to cell death, possibly via apoptosis . Amongst other mechanisms, ER stress pathways have been hypothesized to link to apoptosis . Growing evidence supports that ER could operate in tandem with mitochondria to regulate intracellular Ca2+ fluxes in MPP+-induced cell death.
The caspase cascade responsible for executing cell death following cytochrome c release is well described; however the distinct roles of caspases-9, −3 and −7 during this process are not completely defined. Caspase-9 can remodel mitochondria and increase ROS production by cleaving Bid into tBid. Also, caspase-3 can inhibit ROS production and is the effector caspase necessary for efficient cell killing. In contrast, caspase-7 has no significant role in sensitivity to intrinsic cell death, but it is responsible for ROS production and cell detachment . Our data showed that mitochondria dependent apoptosis triggered by MPP+, assessed by the measurement of caspase 7 and 9 activation, is not prevented by LSA treatment. However, LSA blocks the MPP+-mediated increase in GRP-78 expression and caspase 3 activation suggesting that the ER stress but not the mitochondrial pathway may be regulated by LSA. In the previous studies, the protein levels of GRP-78 in the MN9D cells were up-regulated by 6-OHDA or MPP+ , suggesting that ER stress is indeed a major pathway of MPP+-mediated neuronal apoptosis or a survival effect to save cells. Inhibition of complex I in mitochondria by MPP+ triggers generation of ROS and RNS. As a result of close proximity of mitochondria and ER, critical thiols of IP3R are modified by mitochondrial ROS and RNS. Consequently, IP3R channels are activated thereby enhancing ER Ca2+ release, calpain activation and Bax cleavage. Cleavage of Bax facilitates Bax oligomerization and formation of death pores in the outer mitochondrial membrane that leaks cytochrome c into the cytosol which, in turn, leads to apoptosome formation followed by caspase-9/caspase-3 activation and apoptosis.
The ip-injection of MPTP is the most relevant animal model of PD. On the other hand, to bypass the blood–brain barrier, MPTP is injected stereotactically into the brain. However, icv-injected MPTP induced no lesions in the striatum or SNpc of C57BL/6 mice . It is possible that icv-injected MPTP rapidly disappears from CSF before the conversion to MPP+ and/or that MPTP is detoxified by drug-metabolizing enzymes such as glutathione S-transferase and cytochrome P450. Therefore, icv-injection of MPP+ may be used to prohibit this disadvantage. After icv injection, MPP+ initially affects the dopaminergic cell body in the SNpc and then the striatum to which dopaminergic cells project .
Previously, several polyphenols and polyphenol glycosides have been demonstrated to be neuroprotective against MPP+-mediated neurotoxicity that include puerarin ; tetrahydroxystilbene glucoside ; pedicularioside A ; myricetin ; pinocembrin ; daidzein ; acacetin ; quercetin . Moreover, salvianolic acid (Sal) B and A, were also found to protect SH-SY5Y cells against MPP+-induced apoptosis by relieving oxidative stress and modulating the apoptotic process [48, 49]. The structure of LSA is similar to Sal B and A. In acidic aqueous solution, Sal B are found to be hydrolyzed into LSA, and the latter was transformed into Sal A . In our present study, LSA was found to protect CATH.a cells against MPP+-induced apoptosis by relieving oxidative stress and modulating the apoptotic process.
In conclusion, LSA is potential for novel therapeutic intervention for Parkinson’s disease.
Glial fibrillary acid protein
78 kDa glucose-regulated protein
Ionized calcium-binding adaptor molecule-1
C-jun N-terminal kinase
- MPP+ :
3-[4,5-dimethylthiazol-2-yl]- 2-5-diphenyl-tetrazolium bromide
Poly ADP ribose polymerase
Reactive nitotrogen species
Reactive oxygen species
SN pars compacta
SN pars reticulata
Tournefolic acid B
Tournefolic acid B methyl ester
Tetramethyl Rhodamine Methyl Ester
Unfolding protein response
Burke RE. Programmed cell death and new discoveries in the genetics of parkinsonism. J Neurochem. 2008;104:875–90.
More SV, Kumar H, Kim IS, Song SY, Choi DK. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson’s disease. Mediators Inflamm. 2013;2013:952375.
Nolan YM, Sullivan AM, Toulouse A. Parkinson’s disease in the nuclear age of neuroinflammation. Trends Molecul Med. 2013;19:187–96.
Blandini F, Armentero MT. Animal models of Parkinson’s disease. FEBS J. 2012;279:1156–66.
Bezard E, Yue Z, Kirik D, Spillantini MG. Animal models of Parkinson’s disease: limits and relevance to neuroprotection studies. Mov Disord. 2013;28:61–70.
Olanow CW, Tatton WT. Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 2013;22:123–44.
Ramsay RR, Singer TP. Energy-dependent uptake of 1-methyl-4- phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine, by mitochondria. J Biol Chem. 1986;261:7885–7.
Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, et al. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson’s disease. J Neurosci. 2001;21:9519–28.
Arduino DM, Esteves AR, Cardoso SM, Oliveira CR. Endoplasmic reticulum and mitochondria interplay mediates apoptotic cell death: relevance to Parkinson’s disease. Neurochem Int. 2009;55:341–8.
Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D, Greene LA. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson’s disease. J Neurosci. 2002;22:10690–8.
Holtz WA, O’Malley KL. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem. 2003;278:19367–77.
Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009;8:382–97.
Episcopo FL, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B. Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson’s disease: focus on endogenous neurorestoration. Curr Aging Sci. 2013;6:45–55.
Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 1999;46:598–605.
Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med. 1999;5:1403–9.
Marxreiter F, Regensburger M, Winkler J. Adult neurogenesis in Parkinson’s disease. Cell Mol Life Sci. 2013;70:459–73.
Lin YL, Chang YY, Kuo YH, Shiao MS. Anti-lipid-peroxidative principles from Tournefortia sarmentosa. J Nat Prod. 2002;65:745–7.
Chi CW, Wang CN, Lin YL, Chen CF, Shiao YJ. Tournefolic acid B methyl ester attenuates glutamate-induced toxicity by blockade of ROS accumulation and abrogating the activation of caspases and JNK in rat cortical neurons. J Neurochem. 2005;92:692–700.
Wang CN, Pan HC, Lin YL, Chi CW, Shiao YJ. Ester derivatives of tournefolic acid B attenuate N-methyl-D-aspartate-mediated excitotoxicity in rat cortical neurons. Mol Pharmacol. 2006;69:950–9.
Chi CW, Lin YL, Wang YH, Chen CF, Wang CN, Shiao YJ. Tournefolic acid B attenuates amyloid beta protein-mediated toxicity by abrogating the calcium overload in mitochondria and retarding the caspase 8-truncated Bid-cytochrome c pathway in rat cortical neurons. Eur J Pharmacol. 2008;586:35–43.
Chen J, Wang F, Lee FS, Wang X, Xie M. Separation and identification of water-soluble salvianolic acids from Salvia miltiorrhiza Bunge by high-speed counter-current chromatography and ESI-MS analysis. Talanta. 2006;69:172–9.
Lin YL, Wang CN, Shiao YJ, Liu TY, Wang WY. Benzolignanoid and Polyphenols from Origanum vulgare. J Chin Chem Soc. 2003;50:1079–83.
Liu X, Chen R, Shang Y, Jiao B, Huang C. Lithospermic acid as a novel xanthine oxidase inhibitor has anti-inflammatory and hypouricemic effects in rats. Chem Biol Interact. 2008;176:137–42.
Chen L, Wang WY, Wang YP. Inhibitory effects of lithospermic acid on proliferation and migration of rat vascular smooth muscle cells. Acta Pharmacol Sin. 2009;30:1245–52.
Suri C, Fung BP, Tischler AS, Chikaraishi DM. Catecholaminergic cell lines from the brain and adrenal glands of tyrosine hydroxylase-SV40 T antigen transgenic mice. J Neurosci. 1993;13:1280–91.
Wang CN, Chi CW, Lin YL, Chen CF, Shiao YJ. The neuroprotective effects of phytoestrogens on amyloid β protein-induced toxicity are mediated by abrogating the activation of caspase cascade in rat cortical neurons. J Biol Chem. 2001;276:5287–95.
Dewapriya P, Himaya SW, Li YX, Kim SK. Tyrosol exerts a protective effect against dopaminergic neuronal cell death in in vitro model of Parkinson’s disease. Food Chem. 2013;141:1147–57.
Xu J, Xilouri M, Bruban J, Shioi J, Shao Z, Papazoglou I. Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling. Neurobiol Aging. 2011;32:2326.e5–2326.e16.
Fragkouli A. miR-7 and miR-153 protect neurons against MPP(+)-induced cell death via upregulation of mTOR pathway. Front Cell Neurosci. 2014;8:182.
Huh GY, Glantz SB, Je S, Morrow JS, Kim JH. Calpain proteolysis of alpha II-spectrin in the normal adult human brain. Neurosci Lett. 2001;316:41–4.
Samantaray S, Knaryan VH, Le Gal C, Ray SK, Banik NL. Calpain inhibition protected spinal cord motoneurons against 1-methyl-4-phenylpyridinium ion and rotenone. Neuroscience. 2011;192:263–74.
Harbison RA, Ryan KR, Wilkins HM, Schroeder EK, Loucks FA, Bouchard RJ, et al. Calpain plays a central role in 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity in cerebellar granule neurons. Neurotox Res. 2011;19:374–88.
Polster BM, Fiskum G. Mitochondrial mechanisms of neural cell apoptosis. J Neurochem. 2004;90:1281–9.
Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science. 2003;300:135–9.
Shimoke K, Kudo M, Ikeuchi T. MPTP-induced reactive oxygen species promote cell death through a gradual activation of caspase-3 without expression of GRP78/Bip as a preventive measure against ER stress in PC12 cells. Life Sci. 2003;73:581–93.
De Simoni S, Linard D, Hermans E, Knoops B, Goemaere J. Mitochondrial peroxiredoxin-5 as potential modulator of mitochondria-ER crosstalk in MPP+-induced cell death. J Neurochem. 2013;125:473–85.
Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol. 2001;65:135–72.
Zhang K, Ma Z, Wang J, Xie A, Xie J. Myricetin attenuated MPP(+)-induced cytotoxicity by anti-oxidation and inhibition of MKK4 and JNK activation in MES23.5 cells. Neuropharmacology. 2011;61:329–35.
Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. 2013;14:32.
Ito T, Suzuki K, Uchida K, Nakayama H. Different susceptibility to 1-methyl-4-phenylpyridium (MPP+)-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B). Exp Toxicol Pathol. 2013;65:153–8.
Zhu G, Wang X, Wu S, Li Q. Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP + −induced human neuroblastoma SH-SY5Y cell death. Neurochem Int. 2012;60:400–8.
Sun FL, Zhang L, Zhang RY, Li L. Tetrahydroxystilbene glucoside protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity. Eur J Pharmacol. 2011;660:283–90.
Li YY, Lu JH, Li Q, Zhao YY, Pu XP. Pedicularioside A from Buddleia lindleyana inhibits cell death induced by 1-methyl-4-phenylpyridinium ions (MPP+) in primary cultures of rat mesencephalic neurons. Eur J Pharmacol. 2008;579:134–40.
Wang Y, Gao J, Miao Y, Cui Q, Zhao W, Zhang J, et al. Pinocembrin Protects SH-SY5Y Cells Against MPP(+)-induced neurotoxicity through the mitochondrial apoptotic pathway. J Mol Neurosci. 2014;53:537–45.
Kajta M, Rzemieniec J, Litwa E, Lason W, Lenartowicz M, Krzeptowski W, et al. The key involvement of estrogen receptor β and G-protein-coupled receptor 30 in the neuroprotective action of daidzein. Neuroscience. 2013;238:345–60.
Kim HG, Ju MS, Ha SK, Lee H, Lee H, Kim SY, et al. Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced neuroinflammation in vitro and in vivo. Biol Pharm Bull. 2012;35:1287–94.
Bournival J, Plouffe M, Renaud J, Provencher C, Martinoli MG. Quercetin and sesamin protect dopaminergic cells from MPP+-induced neuroinflammation in a microglial (N9)-neuronal (PC12) coculture system. Oxid Med Cell Longev. 2012;2012:921941.
Zeng G, Tang T, Wu HJ, You WH, Luo JK, Lin Y, et al. Salvianolic acid B protects SH-SY5Y neuroblastoma cells from 1-methyl-4-phenylpyridinium-induced apoptosis. Biol Pharm Bull. 2010;33:1337–42.
Wang XJ, Xu JX. Salvianic acid A protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity. Neurosci Res. 2005;51:129–38.
Kan S, Chen Z, Shao L, Li J. Transformation of salvianolic acid B to salvianolic acid a in aqueous solution and the in vitro liver protective effect of the main products. J Food Sci. 2014;79:C499–504.
This study was supported by Grant NSC-97-2320-B-077-006-MY3 from the National Science Council, Grant NRICM-98-DBCM-06 from the National Research Institute of Chinese Medicine, Taiwan, Republic of China.
The authors declare that they have no competing of interests.
YLL: contributed the isolation and purification LSA and TABM. HJT: participated in the design of the study and performed the statistical analysis. THL and TTT: carried out the cell culture and animal experiment, immunoassays and neurotoxicity assay. YJS: substantial contributions to the conception and design of the work, analysis, figure editing and coordination to draft the manuscript.
Yun-Lian Lin and Huey-Jen Tsay contributed equally to this work.